Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Subset analysis of NAT2 acetylator status and severity grade confirmed these results in AT-DILI patients with more severe disease whereas fast and intermediate acetylator phenotypes were associated with a decreased AT-DILI risk.
|
31699005 |
2019 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Association of Nat2 Gene Polymorphism with Antitubercular Drug-induced Hepatotoxicity in the Eastern Uttar Pradesh Population.
|
31245212 |
2019 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Relevance of NAT2 genotype to anti-tuberculosis drug-induced hepatotoxicity in a Chinese Han population.
|
31066138 |
2019 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The aim of this study is to evaluate the potential association between N-acetyltransferase type 2 (NAT2) polymorphisms and drug-induced liver injury during anti-TB treatment (AT-DILI).
|
30047605 |
2018 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
|
29781872 |
2018 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Two SNPs in NAT2 (rs1041983 and rs1495741) and NAT2 slow acetylators (SA) were significantly associated with INH-DILI (OR (95% CI) = 13.86 (4.30-44.70), 0.10 (0.03-0.33) and 9.98 (3.32-33.80), respectively).
|
29036176 |
2017 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
In conclusion, this study confirms the significance of the association between slow-acetylator NAT2 variants and susceptibility to AT-DILI in an Indonesian population.
|
26911349 |
2016 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Phenotype frequencies of the NAT2 acetylator in AT-DILI patients were respectively 71.7%, 22.6% and 5.7% for slow, intermediate and rapid acetylators.
|
27725049 |
2016 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
This study was aimed to investigate the role of NAT2 gene polymorphism in anti-tuberculosis drug-induced hepatotoxicity (DIH).
|
28474630 |
2016 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.
|
26616266 |
2015 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
A recent clinical trial used N-acetyltransferase 2 genotyping to determine the appropriate dose of isoniazid in an anti-tuberculosis therapeutic regimen and demonstrated that pharmacogenetic-based clinical algorithms have the potential to improve efficacy of a drug and to reduce DILI.
|
25809692 |
2015 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity.
|
25693865 |
2015 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The NAT2 slow acetylator genotype appears to be a significant risk factor for moderate and severe drug- induced liver injury.
|
24888881 |
2014 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Though the associations with non-HLA genes have been less well replicated than the HLA associations, there is increasing evidence that drug metabolism genes such as NAT2 and UGT2B7 contribute to some forms of DILI.
|
24879978 |
2014 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Among the patient-specific determinants of susceptibility to INH-associated DILI, the importance of HLA genetic variants has been increasingly recognized, whereas the role of polymorphisms of drug-metabolizing enzymes (NAT2 and CYP2E1) has become less important and remains controversial.
|
24783247 |
2014 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity.
|
23407048 |
2013 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population.
|
22947533 |
2013 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis.
|
23277397 |
2013 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
|
23875638 |
2013 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
To evaluate whether polymorphism of the NAT2 gene was associated with antituberculosis drug-induced hepatotoxicity in Tunisian patients.
|
21856096 |
2012 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
However, the combination of the CYP2E1 C1/C1 genotype with a slow acetylator NAT2 genotype increased the risk of anti-TB drug-induced hepatotoxicity (OR 5.33; P = 0.003) compared with the combination of a rapid acetylator NAT2 genotype with either a C1/C2 or C2/C2 genotype.5.
|
22506592 |
2012 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
|
22409928 |
2012 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians.
|
22283902 |
2011 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
For genes relevant to drug metabolism, the best replicated association is between isoniazid DILI and NAT2 slow acetylation.
|
20415545 |
2010 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Conclusive evidence for association with DILI risk has been obtained for non-mutated CYP2E1, slow NAT2 and slow GSTM1 genotypes.
|
20214588 |
2009 |